Brief: Cardiol Therapeutics Says It Has Exceeded 50% Enrollment In Its Phase II Trial In Acute Myocarditis
09/01/2024 12:40
Jan 9 (Reuters) - Cardiol Therapeutics Inc CRDL.TO :
* CARDIOL THERAPEUTICS INC: IT HAS EXCEEDED 50% ENROLLMENT
IN ITS
PHASE II ARCHER TRIAL IN ACUTE MYOCARDITIS
Further company coverage: CRDL.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cardiol Therapeutics
See all newsBrief: Cardiol Therapeutics Achieves Phase III Maveric Enrollment Target Ahead Of Schedule And Expands Pivotal Trial To Strengthen Assessment Of Cardiolrx's Efficacy
Brief: Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus
Brief: Cardiol Therapeutics Files For Mixed Shelf Offering Of Up To $150 Mln
Brief: Cardiol Therapeutics Initiated Pivotal Phase Iii Maveric Trial Of Cardiolrx In Recurrent Pericarditis
NASDAQ RESUMED AT 09:00 AM